Operational Costs Compared: SG&A Analysis of Alkermes plc and Geron Corporation

A Decade of SG&A Trends: Alkermes plc vs. Geron Corporation

In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Alkermes plc and Geron Corporation have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a strategic expansion and investment in operational capabilities. In contrast, Geron Corporation's SG&A expenses grew by about 312%, albeit from a much smaller base, indicating a focused yet aggressive approach to scaling operations.

Key Insights

• Alkermes plc: Starting at 200 million in 2014, their SG&A expenses peaked at nearly 690 million by 2023, highlighting a consistent upward trend.
• Geron Corporation: Despite a smaller scale, their expenses rose from 17 million to nearly 69 million, marking a significant growth trajectory.

These trends underscore the diverse strategies employed by these companies in navigating the competitive pharmaceutical industry.